Cargando…
Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced st...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169581/ https://www.ncbi.nlm.nih.gov/pubmed/37180144 http://dx.doi.org/10.3389/fimmu.2023.1073531 |
_version_ | 1785039068654993408 |
---|---|
author | Zhang, Zunyi Zhang, Erlei |
author_facet | Zhang, Zunyi Zhang, Erlei |
author_sort | Zhang, Zunyi |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced stage, and resection is only suggested for a minority of such patients. Recently, advances in systemic and locoregional treatments for such patients have resulted in amazing response rates. Therefore, a “conversion therapy” strategy including systemic and locoregional treatments is proposed to select patients from an initially unresectable state to eventually undergo R0 resection. Recently, many studies have proven that conversion therapy followed by subsequent surgery is achievable in well-selected advanced HCC patients and can provide prolonged long-term outcomes. Based on published research, this review has summarized the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion. |
format | Online Article Text |
id | pubmed-10169581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101695812023-05-11 Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review Zhang, Zunyi Zhang, Erlei Front Immunol Immunology Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced stage, and resection is only suggested for a minority of such patients. Recently, advances in systemic and locoregional treatments for such patients have resulted in amazing response rates. Therefore, a “conversion therapy” strategy including systemic and locoregional treatments is proposed to select patients from an initially unresectable state to eventually undergo R0 resection. Recently, many studies have proven that conversion therapy followed by subsequent surgery is achievable in well-selected advanced HCC patients and can provide prolonged long-term outcomes. Based on published research, this review has summarized the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10169581/ /pubmed/37180144 http://dx.doi.org/10.3389/fimmu.2023.1073531 Text en Copyright © 2023 Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Zunyi Zhang, Erlei Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title | Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title_full | Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title_fullStr | Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title_full_unstemmed | Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title_short | Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
title_sort | conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169581/ https://www.ncbi.nlm.nih.gov/pubmed/37180144 http://dx.doi.org/10.3389/fimmu.2023.1073531 |
work_keys_str_mv | AT zhangzunyi conversiontherapyforadvancedhepatocellularcarcinomawithvascularinvasionacomprehensivereview AT zhangerlei conversiontherapyforadvancedhepatocellularcarcinomawithvascularinvasionacomprehensivereview |